Cross-Border Impact Ventures: Investment Portfolio & Startup News
Cross-Border Impact Ventures
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
TidalSense secures £14m in funding from VCs to roll out AI-driven breath test for lung disease
TidalSense is a respiratory diagnostics business in Cambridge that has developed N-Tidal Diagnose, a handheld device and software combination which records a patient breathing normally for 75 seconds and applies AI models to detect chronic obstructive pulmonary disease. Intended for use in primary and community care by any trained healthcare professional, N-Tidal Diagnose removes the need for the forced exhalation and specialist supervision that conventional lung function testing requires.
OXcan raises £9m Series A led by We Venture Capital and Cross-Border Impact Ventures to revolutionise early lung cancer detection
OXcan develops blood-based liquid biopsy tests using proteomics and AI to detect lung cancer at earlier stages, enabling minimally invasive screening designed to improve outcomes and reduce pressure on healthcare systems.
More venture news
- 30 Sept 2026
ZenithonZenithon raises a £7.5m seed round led by BACKED for ML models that solves complex physics
EquityDeep Tech - 30 Sept 2026
Inovus MedicalInovus Medical lands £7m extension led by PXN Group to provide surgeons with surgical simulation training
EquityHealth - 29 Sept 2026
Something & NothingSomething & Nothing unlocks £5m in funding led by Venrex for premium soft drinks built on flavour
EquityConsumer
